. 2024 Feb 8;45:100743. doi: 10.1016/j.ctro.2024.100743

Table 1.

Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
Signed study Informed Consent Form Karnofsky Performance Status (KPS) ≥ 60 % Age ≥ 60 years Patients with histologically proven cSCC or BCC Patients requiring radiotherapy treatment according to dermato-oncology tumor board: patients who cannot undergo surgical procedure or patients who decline surgical resection and/or anatomical locations where surgery can compromise function or cosmesis.T1-T2 N0 M0 lesions with a small (T1; lesion ≤ 2 cm in diameter) or large (T2; 2 cm < lesion ≤ 4 cm) volume (TNM UICC, 8th Edition) Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated	Previous radiotherapy in the treated area Concomitant auto-immune disease with skin lesions Concomitant use of radio-sensitizer drug Cognitive disorders, not compatible with the signature of informed consentCurrent, recent (within 10 days prior start of study treatment), or planned participation in an experimental drug study (before EOT visit)Concomitant use of systemic oncological treatment for a cancer other than the skin cancer (s)

Inclusion criteria

Exclusion criteria

Signed study Informed Consent Form
Karnofsky Performance Status (KPS) ≥ 60 %
Age ≥ 60 years
Patients with histologically proven cSCC or BCC
Patients requiring radiotherapy treatment according to dermato-oncology tumor board: patients who cannot undergo surgical procedure or patients who decline surgical resection and/or anatomical locations where surgery can compromise function or cosmesis.T1-T2 N0 M0 lesions with a small
(T1; lesion ≤ 2 cm in diameter) or large (T2; 2 cm < lesion ≤ 4 cm) volume (TNM UICC, 8th Edition)
Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated

Previous radiotherapy in the treated area
Concomitant auto-immune disease with skin lesions
Concomitant use of radio-sensitizer drug
Cognitive disorders, not compatible with the signature of informed consentCurrent, recent
(within 10 days prior start of study treatment), or planned participation in an experimental drug study (before EOT visit)Concomitant use of systemic oncological treatment for a cancer other than the skin cancer
(s)